Tenax Therapeutics Inc. (TENX) stock rises in the current market trading by 16.39% after TENX announced the promising data from TENX’s Phase 2 HELP study. Tenax Therapeutics is a specialized pharmaceutical company dedicated to discovering, developing, and selling drugs that meet unmet patient needs in cardiovascular and pulmonary diseases. TENX has a world-class scientific advisory board that includes internationally recognized, pulmonary hypertension experts.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
What is happening?
Phase Positive from TENX’s results 2 HELP Study, which tested levosimendan in patients with pulmonary hypertension and heart failure with retained ejection fraction, were published today (PH-HFpEF). The new study was published in the Journal of the American College of Cardiology and is named Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF, the Results of the Placebo-Controlled HELP Trial.
Outcomes of the Trial
- In the initial open-label lead-in step of the trial led by TENX, 84 percent of PH-HFpEF patients did respond to levosimendan due to predefined parameters.
- Levosimendan enhanced cardiovascular hemodynamics and exercise potential in PH-HFpEF patients.
- Levosimendan improved 6-minute walk distance significantly and was the only treatment to do so in a randomized, double-blind, placebo-controlled trial of PH-HFpEF patients.
- In PH-HFpEF patients, levosimendan was well received.
Dr. Daniel Burkhoff, MD Ph.D. who is the Director of Heart Failure, Hemodynamics and Mechanical Circulatory Support Research at Cardiovascular Research Foundation, is the first author on the publication and directed the blinded hemodynamic core lab and study for the Aid trial. He mentioned that the cardiovascular hemodynamic effects seen in this trial after administration of levosimendan were remarkable, particularly in the first 24 hours. Reduced cardiac filling pressures and their links to enhanced exercise efficiency are important early indicators of clinical gain and indicate significant changes in PH-HFpEF patients’ well-being. Levosimendan may have a significant effect on the treatment of PH-HFpEF.”